Novel opportunities for next-generation probiotics targeting metabolic syndrome

Patrice D Cani; Matthias Van Hul

doi:10.1016/j.copbio.2014.10.006

Novel opportunities for next-generation probiotics targeting metabolic syndrome

Curr Opin Biotechnol. 2015 Apr:32:21-27. doi: 10.1016/j.copbio.2014.10.006. Epub 2014 Oct 29.

Authors

Patrice D Cani¹, Matthias Van Hul²

Affiliations

¹ Université Catholique de Louvain, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), Metabolism and Nutrition Research Group, Av. E. Mounier, 73 Box B1.73.11, B-1200 Brussels, Belgium. Electronic address: patrice.cani@uclouvain.be.
² Université Catholique de Louvain, Louvain Drug Research Institute, WELBIO (Walloon Excellence in Life Sciences and BIOtechnology), Metabolism and Nutrition Research Group, Av. E. Mounier, 73 Box B1.73.11, B-1200 Brussels, Belgium.

PMID: 25448228
DOI: 10.1016/j.copbio.2014.10.006

Abstract

Various studies have described the beneficial effects of specific bacteria on the characteristics of metabolic syndrome. Intestinal microbiota might therefore represent a modifiable trait for translational intervention to improve the metabolic profiles of obese and type 2 diabetic patients. However, identifying potential probiotic strains that can effectively colonize the gastrointestinal tract and significantly affect host metabolism has been challenging. This review aims to summarize the notable advances and contributions in the field that may prove useful for identifying next-generation probiotics that target metabolic syndrome and its related disorders.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Amidohydrolases / metabolism
Animals
Bifidobacterium / metabolism
Humans
Intestinal Mucosa / metabolism
Lactobacillus / metabolism
Metabolic Syndrome / diet therapy*
Probiotics / therapeutic use*

Substances

Amidohydrolases
choloylglycine hydrolase